Curcumin: the yellow pigment of the turmeric rhizome
Curcumin is the substance that gives turmeric its colour, and it is one of the most frequently investigated plant compounds in the scientific literature. The number of publications is large; the number of clear conclusions is much smaller. This article describes the chemistry of the molecule, its origin, the central problem of its bioavailability, and what the research literature reports.
The plant
Curcuma longa is a perennial herbaceous plant of the ginger family, Zingiberaceae. It grows to about one metre, needs a warm and humid climate, and is cultivated above all in India, which accounts for the largest share of world production, as well as in China, Indonesia, Bangladesh and parts of Latin America. The part used is the rhizome, an underground stem that is harvested after eight to ten months, boiled, dried and ground into the familiar yellow powder.
Chemistry
Curcumin, chemically diferuloylmethane with the formula C21H20O6, belongs to the polyphenols and more specifically to the diarylheptanoids. Two substituted phenol rings are joined by a seven-carbon chain containing a 1,3-diketone group. In solution the molecule exists in equilibrium between the keto form and the enol form; the enol form dominates in most solvents and is responsible for the conjugated system that produces the intense yellow colour.
Dried turmeric powder contains roughly two to five percent curcuminoids. This mixture is made up of three closely related compounds: curcumin, which accounts for about three quarters, demethoxycurcumin and bisdemethoxycurcumin. Extracts standardised to 95 percent curcuminoids are produced by solvent extraction of the rhizome followed by crystallisation.
Two chemical properties shape everything that follows: the molecule is practically insoluble in water at acidic and neutral pH, and it is unstable at alkaline pH, where it degrades within minutes into vanillin, ferulic acid and feruloylmethane.
History and isolation
Turmeric has been used in India for more than two thousand years as a spice, as a dye and in ayurvedic practice. The compound itself was first isolated in 1815 by Vogel and Pelletier, obtained in crystalline form in 1870, and its structure was determined in 1910 by Milobedzka and Lampe, who achieved its synthesis three years later. Systematic laboratory research began in the middle of the twentieth century and expanded greatly from the 1990s onwards.
The bioavailability problem
Pharmacokinetic studies agree on a clear picture. After oral intake, curcumin is poorly absorbed, and the fraction that enters the intestinal wall and the liver is rapidly conjugated to glucuronides and sulfates. Plasma concentrations of the unconjugated compound measured after gram doses lie in the nanomolar range or below the limit of detection of the assay, while the concentrations at which effects are observed in cell culture typically lie in the micromolar range. A large part of an oral dose is also metabolised by the gut microbiota.
Formulation approaches that address this are:
- Piperine: an alkaloid of black pepper that inhibits glucuronidation. A frequently cited 1998 study in eight volunteers reported a substantial rise in measured plasma values when 2 g of curcumin was taken with 20 mg of piperine. Piperine itself inhibits drug-metabolising enzymes, which is relevant for interactions.
- Phospholipid complexes: curcumin bound to phosphatidylcholine, sold under names such as Meriva, with pharmacokinetic studies reporting higher plasma values of total curcuminoids.
- Liposomes and micelles: the compound is enclosed in lipid vesicles or in surfactant micelles to carry it through the aqueous phase of the gut.
- Nanoparticles and solid dispersions: reducing particle size and changing the crystalline state raise the dissolution rate.
- Intake with fat: because the molecule is lipophilic, studies administer it with a fat-containing meal.
Comparisons between these formulations are difficult because studies measure different analytes, some reporting free curcumin and others total curcuminoids after enzymatic deconjugation.
A methodological debate
Curcumin is one of the compounds that medicinal chemists classify as a PAINS substance, a pan-assay interference compound. A review published in 2017 in the Journal of Medicinal Chemistry set out the argument: the molecule is chemically unstable, reacts covalently with proteins, interferes with common assay readouts through fluorescence and membrane disruption, and therefore produces apparent activity across a very wide range of biochemical screens. The authors concluded that, despite thousands of publications and many clinical studies, no double-blind, placebo-controlled trial had established a specific clinical result. This critique is an important part of the context for any reading of the literature on this compound.
Research findings
What follows is a summary of what studies report, with the model and the limitations stated:
- Cell culture: in isolated cells, curcumin has been described as acting on a long list of molecular targets, among them the transcription factor NF-kappaB and various kinases. These observations were made at concentrations that oral intake does not reach in human plasma.
- Osteoarthritis of the knee: a number of randomised trials with between 40 and 160 participants have compared curcuminoid preparations with placebo or with non-steroidal analgesics over periods of four to sixteen weeks, using pain and function scores. Systematic reviews describe these trials as small, heterogeneous in preparation and dose, often short and frequently funded by manufacturers, and rate the certainty of the evidence as low.
- Ulcerative colitis: a Japanese trial published in 2006 randomised 89 patients in remission to 2 g of curcumin daily or placebo alongside standard therapy over six months and reported a difference in the relapse rate. Later trials were likewise small.
- Metabolic parameters: trials have measured fasting glucose, HbA1c and blood lipids during curcuminoid intake. Meta-analyses of these trials report differences of varying size, with high statistical heterogeneity between studies.
- Oncology: phase I and phase II studies have examined tolerability and plasma kinetics in patients, including doses of up to 8 g per day. These studies characterise exposure; they are not evidence of a clinical result.
- Mood: small randomised trials with 50 to 120 participants have used depression rating scales during curcuminoid intake. Reviews point to the small samples, the short duration and the unclear mechanism.
Doses used in published trials range from 500 mg to 8 g of curcuminoids per day, usually as extracts standardised to 95 percent. These are study doses, stated here for context.
Safety data and interactions
- As a food colour, curcumin carries the number E 100. JECFA and EFSA have set an acceptable daily intake of 0 to 3 mg per kilogram of body weight, a value that relates to use as an additive.
- Gastrointestinal complaints such as nausea, diarrhoea and abdominal discomfort are reported at higher doses.
- Since 2019, European medicines and food safety authorities have recorded case reports of liver injury associated with high-dose turmeric supplements, many of them involving preparations with added piperine or with raised bioavailability. Several countries now require a warning on such products.
- An interaction with anticoagulant medicines is discussed. Piperine-containing products can alter the metabolism of other medicines through inhibition of cytochrome P450 enzymes and glucuronidation.
- Caution is advised in gallstone disease and bile duct obstruction, since turmeric preparations stimulate bile flow.
- Data for amounts beyond culinary use in pregnancy and breastfeeding are insufficient.
- Curcumin can bind iron; the relevance of this for people with low iron status is discussed in the literature.
Regulatory status
Turmeric and curcumin extracts are marketed in the EU as foods and food supplements, and curcumin is authorised as the food colour E 100. No health claim for curcumin has been authorised under Regulation (EC) No 1924/2006. Statements about physiological function in advertising are therefore not permitted.